A comparison of sustained-release bupropion and placebo for smoking cessation

Richard D. Hurt, David P L Sachs, Elbert D. Glover, Kenneth P. Offord, J. Andrew Johnston, Lowell C. Dale, Moise A. Khayrallah, Darrell R. Schroeder, Penny N. Glover, C. Rollynn Sullivan, Ivana T Croghan, Pamela M. Sullivan

Research output: Contribution to journalArticle

1150 Citations (Scopus)

Abstract

Background and Methods: Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo- controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or 'target quit date') was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. Results: At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) - but not the 100-mg group (P = 0.09) - were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. Conclusions: A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.

Original languageEnglish (US)
Pages (from-to)1195-1202
Number of pages8
JournalNew England Journal of Medicine
Volume337
Issue number17
DOIs
StatePublished - Oct 23 1997

Fingerprint

Bupropion
Smoking Cessation
Placebos
Depression
Carbon Monoxide
Weight Gain
Therapeutics
Antidepressive Agents
Counseling
Smoking
Air
Equipment and Supplies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., ... Sullivan, P. M. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine, 337(17), 1195-1202. https://doi.org/10.1056/NEJM199710233371703

A comparison of sustained-release bupropion and placebo for smoking cessation. / Hurt, Richard D.; Sachs, David P L; Glover, Elbert D.; Offord, Kenneth P.; Johnston, J. Andrew; Dale, Lowell C.; Khayrallah, Moise A.; Schroeder, Darrell R.; Glover, Penny N.; Sullivan, C. Rollynn; Croghan, Ivana T; Sullivan, Pamela M.

In: New England Journal of Medicine, Vol. 337, No. 17, 23.10.1997, p. 1195-1202.

Research output: Contribution to journalArticle

Hurt, RD, Sachs, DPL, Glover, ED, Offord, KP, Johnston, JA, Dale, LC, Khayrallah, MA, Schroeder, DR, Glover, PN, Sullivan, CR, Croghan, IT & Sullivan, PM 1997, 'A comparison of sustained-release bupropion and placebo for smoking cessation', New England Journal of Medicine, vol. 337, no. 17, pp. 1195-1202. https://doi.org/10.1056/NEJM199710233371703
Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC et al. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine. 1997 Oct 23;337(17):1195-1202. https://doi.org/10.1056/NEJM199710233371703
Hurt, Richard D. ; Sachs, David P L ; Glover, Elbert D. ; Offord, Kenneth P. ; Johnston, J. Andrew ; Dale, Lowell C. ; Khayrallah, Moise A. ; Schroeder, Darrell R. ; Glover, Penny N. ; Sullivan, C. Rollynn ; Croghan, Ivana T ; Sullivan, Pamela M. / A comparison of sustained-release bupropion and placebo for smoking cessation. In: New England Journal of Medicine. 1997 ; Vol. 337, No. 17. pp. 1195-1202.
@article{ac98b8d9e168454ab5c42f1cd9dbb0c0,
title = "A comparison of sustained-release bupropion and placebo for smoking cessation",
abstract = "Background and Methods: Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo- controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or 'target quit date') was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. Results: At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) - but not the 100-mg group (P = 0.09) - were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. Conclusions: A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.",
author = "Hurt, {Richard D.} and Sachs, {David P L} and Glover, {Elbert D.} and Offord, {Kenneth P.} and Johnston, {J. Andrew} and Dale, {Lowell C.} and Khayrallah, {Moise A.} and Schroeder, {Darrell R.} and Glover, {Penny N.} and Sullivan, {C. Rollynn} and Croghan, {Ivana T} and Sullivan, {Pamela M.}",
year = "1997",
month = "10",
day = "23",
doi = "10.1056/NEJM199710233371703",
language = "English (US)",
volume = "337",
pages = "1195--1202",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "17",

}

TY - JOUR

T1 - A comparison of sustained-release bupropion and placebo for smoking cessation

AU - Hurt, Richard D.

AU - Sachs, David P L

AU - Glover, Elbert D.

AU - Offord, Kenneth P.

AU - Johnston, J. Andrew

AU - Dale, Lowell C.

AU - Khayrallah, Moise A.

AU - Schroeder, Darrell R.

AU - Glover, Penny N.

AU - Sullivan, C. Rollynn

AU - Croghan, Ivana T

AU - Sullivan, Pamela M.

PY - 1997/10/23

Y1 - 1997/10/23

N2 - Background and Methods: Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo- controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or 'target quit date') was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. Results: At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) - but not the 100-mg group (P = 0.09) - were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. Conclusions: A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.

AB - Background and Methods: Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo- controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or 'target quit date') was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less. Results: At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P = 0.02) and the 300-mg group (P = 0.01) - but not the 100-mg group (P = 0.09) - were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P = 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups. Conclusions: A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.

UR - http://www.scopus.com/inward/record.url?scp=0030720886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030720886&partnerID=8YFLogxK

U2 - 10.1056/NEJM199710233371703

DO - 10.1056/NEJM199710233371703

M3 - Article

C2 - 9337378

AN - SCOPUS:0030720886

VL - 337

SP - 1195

EP - 1202

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 17

ER -